NL195094C - Farmaceutische preparaat dat opgelost cyclosporine bevat en werkwijze voor de bereiding daarvan. - Google Patents

Farmaceutische preparaat dat opgelost cyclosporine bevat en werkwijze voor de bereiding daarvan. Download PDF

Info

Publication number
NL195094C
NL195094C NL8802275A NL8802275A NL195094C NL 195094 C NL195094 C NL 195094C NL 8802275 A NL8802275 A NL 8802275A NL 8802275 A NL8802275 A NL 8802275A NL 195094 C NL195094 C NL 195094C
Authority
NL
Netherlands
Prior art keywords
solution
cyclosporine
monolaurate
cyclosporin
ciclosporin
Prior art date
Application number
NL8802275A
Other languages
English (en)
Dutch (nl)
Other versions
NL8802275A (nl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NL8802275A publication Critical patent/NL8802275A/nl
Application granted granted Critical
Publication of NL195094C publication Critical patent/NL195094C/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL8802275A 1987-09-15 1988-09-15 Farmaceutische preparaat dat opgelost cyclosporine bevat en werkwijze voor de bereiding daarvan. NL195094C (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3730909 1987-09-15
DE3730909 1987-09-15
DE3802355 1988-01-27
DE3802355 1988-01-27

Publications (2)

Publication Number Publication Date
NL8802275A NL8802275A (nl) 1989-04-03
NL195094C true NL195094C (nl) 2003-12-17

Family

ID=25859774

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8802275A NL195094C (nl) 1987-09-15 1988-09-15 Farmaceutische preparaat dat opgelost cyclosporine bevat en werkwijze voor de bereiding daarvan.

Country Status (24)

Country Link
JP (1) JP3090666B2 (ja)
KR (1) KR0131084B1 (ja)
AT (1) AT395819B (ja)
AU (1) AU628787B2 (ja)
BE (1) BE1001204A5 (ja)
CA (1) CA1338775C (ja)
CH (1) CH683672A5 (ja)
DK (1) DK175132B1 (ja)
ES (1) ES2012118A6 (ja)
FI (1) FI94837C (ja)
FR (1) FR2620336B1 (ja)
GB (1) GB2209671B (ja)
GR (1) GR1002243B (ja)
HU (1) HU205010B (ja)
IE (1) IE61195B1 (ja)
IL (1) IL87746A (ja)
IT (1) IT1224886B (ja)
LU (1) LU87335A1 (ja)
MY (1) MY103769A (ja)
NL (1) NL195094C (ja)
NO (1) NO179434C (ja)
NZ (1) NZ226163A (ja)
PT (1) PT88492B (ja)
SE (1) SE503279C2 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
GR1000466B (el) * 1989-01-28 1992-07-30 Sandoz Ag Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης.
BE1003009A5 (fr) * 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.
GB8916901D0 (en) 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
ES2098739T3 (es) 1992-05-13 1997-05-01 Sandoz Ltd Composiciones oftalmicas conteniendo una cyclosporin.
EP0589843B1 (en) 1992-09-25 2001-11-28 Novartis AG Pharmaceutical compositions containing cyclosporins
DE69426408T2 (de) 1993-09-28 2001-07-12 Novartis Ag, Basel Herstellung von Weichgelatinekapseln
RU2158601C2 (ru) 1994-11-03 2000-11-10 Новартис Аг Новые лекарственные формы циклоспорина для орального применения с простым составом и высокой биодоступностью и способ их получения
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
DE19549852B4 (de) 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
TW414696B (en) * 1996-07-01 2000-12-11 Mitsubishi Kagaku Foods Kk Anti-bacteria agent
DE29824679U1 (de) 1997-01-30 2002-03-28 Novartis Ag, Basel Pharmazeutische Zusammensetzungen
GB2326337A (en) * 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1558215A4 (en) * 2003-10-14 2007-09-12 Wockhardt Ltd STERILE GELIFYING AGENTS
JP5422871B2 (ja) * 2006-10-24 2014-02-19 不二製油株式会社 イソフラボン類組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL284933A (ja) * 1961-10-31
GB1134878A (en) * 1966-05-12 1968-11-27 Suga Kazuo Improvements in and relating to oryzanol solutions and compositions
FR5986M (ja) * 1966-11-22 1968-06-21
BE787842A (fr) * 1971-08-25 1972-12-18 Sumito Chemical Cy Ltd Procede de preparation d'une suspension aqueuse de cristaux stables du type non beta d'esters d'acides gras superieurs du chloramphenicol
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
JPS57128634A (en) * 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
JPS61280435A (ja) * 1985-04-04 1986-12-11 Kanji Takada サイクロスポリン類のリンパ指向性製剤

Also Published As

Publication number Publication date
CA1338775C (en) 1996-12-10
FR2620336B1 (fr) 1991-10-25
HU205010B (en) 1992-03-30
DK175132B1 (da) 2004-06-14
KR890004694A (ko) 1989-05-09
PT88492A (pt) 1988-10-01
HUT49494A (en) 1989-10-30
CH683672A5 (de) 1994-04-29
AT395819B (de) 1993-03-25
AU2217288A (en) 1989-04-27
GR880100602A (el) 1989-06-22
ES2012118A6 (es) 1990-03-01
IT8848349A0 (it) 1988-09-14
SE503279C2 (sv) 1996-05-13
NL8802275A (nl) 1989-04-03
GB8821443D0 (en) 1988-10-12
NO884052D0 (no) 1988-09-13
LU87335A1 (fr) 1989-04-06
ATA224988A (de) 1992-08-15
SE8803221D0 (sv) 1988-09-13
JPH01151526A (ja) 1989-06-14
GB2209671B (en) 1991-11-13
NO884052L (no) 1989-03-16
NO179434C (no) 1996-10-09
PT88492B (pt) 1993-03-31
IL87746A (en) 1992-07-15
IE882772L (en) 1989-03-15
GB2209671A (en) 1989-05-24
MY103769A (en) 1993-09-30
FI94837B (fi) 1995-07-31
FI884192A0 (fi) 1988-09-13
FR2620336A1 (fr) 1989-03-17
AU628787B2 (en) 1992-09-24
DK511188D0 (da) 1988-09-14
IL87746A0 (en) 1989-02-28
BE1001204A5 (fr) 1989-08-16
FI94837C (fi) 1995-11-10
IE61195B1 (en) 1994-10-19
JP3090666B2 (ja) 2000-09-25
SE8803221L (sv) 1989-03-16
FI884192A (fi) 1989-03-16
KR0131084B1 (ko) 1998-04-17
NZ226163A (en) 1991-08-27
IT1224886B (it) 1990-10-24
GR1002243B (en) 1996-04-22
DK511188A (da) 1989-03-16
NO179434B (no) 1996-07-01

Similar Documents

Publication Publication Date Title
NL195094C (nl) Farmaceutische preparaat dat opgelost cyclosporine bevat en werkwijze voor de bereiding daarvan.
US5756450A (en) Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
JP4761093B2 (ja) オメガ−３脂肪酸油を含む医薬組成物
KR100188305B1 (ko) 신규의 시클로스포린 결정 형태, 이것의 제조 방법 및 이것을 함유한 약학 조성물 및 그 용도
RU2158601C2 (ru) Новые лекарственные формы циклоспорина для орального применения с простым составом и высокой биодоступностью и способ их получения
HUT73664A (en) Pharmaceutically acceptable improved compositions containing an alcohol and a hydrophobic drug
JP2002513750A (ja) 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
JP2001505928A (ja) シクロスポリン及び陰イオン性界面活性剤を含む固体医薬組成物
HU218934B (hu) Ciklosporintartalmú folyékony gyógyszerkészítmények és eljárás előállításukra
JP2006206615A (ja) 経口投与用シクロスポリン含有新規製剤
JP2003507343A (ja) 経口及び局所投与用の医薬組成物
RU2174394C2 (ru) Фармацевтические композиции, содержащие производные n-сульфонилиндолина
EP1151755B1 (en) Pharmaceutical compositions comprising cyclosporin as active ingredient
JP2002533401A (ja) シクロスポリン溶液
US6258783B1 (en) Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
KR0173349B1 (ko) 사이클로스포린-함유 고체 분산체 조성물
DE3830494A1 (de) Wasserloesliche monoester als solubilisatoren fuer pharmakologische wirkstoffe und pharmazeutische hilfsstoffe
SK123299A3 (en) Pharmaceutical compositions containing cyclosporin
HU212727B (en) Process for producing pharmaceutical compositions in form of microemulsion-prae-concentrate or microemulsion containing cyclosporin(s) as active component

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
CNR Transfer of rights (patent application after its laying open for public inspection)

Free format text: NOVARTIS AG

NP1G Patent granted (not automatically) [patent specification modified]
V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20080915